Neurogenic locus notch homolog protein (Notch receptor) (Notch)

The Notch receptor family, comprising four highly conserved transmembrane proteins (Notch1, Notch2, Notch3, and Notch4), plays a fundamental role in cell fate determination and tissue homeostasis through juxtacrine signaling [1, 2]. Upon binding to membrane-bound ligands such as Jagged or Delta-like on adjacent cells, these receptors undergo sequential proteolytic cleavages, with the final step mediated by the gamma-secretase complex [1, 6]. This process releases the Notch intracellular domain (NICD), which translocates to the nucleus to act as a transcriptional co-activator, regulating genes involved in differentiation, proliferation, and apoptosis [1, 12]. Dysregulation of Notch signaling is implicated in a wide array of pathologies, most notably in cancers such as T-cell acute lymphoblastic leukemia (T-ALL) and various solid tumors, where it often acts as an oncogene [2, 14]. Beyond oncology, mutations in specific Notch receptors are linked to developmental disorders like Alagille syndrome and vascular diseases such as CADASIL [2, 11, 18]. Therapeutic strategies targeting this pathway include gamma-secretase inhibitors (GSIs), which provide pan-Notch inhibition, and monoclonal antibodies designed to target specific receptors or ligands to minimize off-target toxicities [6, 15, 17]. However, clinical development has been challenged by significant safety concerns, particularly gastrointestinal toxicity resulting from the inhibition of Notch signaling in the intestinal epithelium [6].

Other names

Neurogenic locus notch homolog proteinhNotchTAN1Int-3Notch 1-4Notch receptor family

Inhibition of gamma-secretase-mediated proteolytic cleavage; Blocking of ligand-receptor interaction; Inhibition of the Notch transcriptional activation complex